

July 15th, 2022

Market Data

Arihant Capital values your support in the Asiamoney Brokers Poll 2022 for Institutional Team. We request your ballot

ASIAMONEY

Click Here

Index	Closing	% Chg	% YTD
BSE Sensex	53416.15	-0.18	-8.30
Nifty 50	15938.65	-0.18	-8.16
Nifty Midcap 50	7649.95	-0.14	-9.05
BSE Smallcap	25645.68	-0.56	-12.94

World Indices	Closing	% Chg	% YTD
Nikkei	26625.00	-0.05	-7.52
Hang Sang	20751.21	-0.07	-11.31
Dow Jones	30630.17	-0.46	-15.71
Nasdaq	11768.39	0.34	-27.89
FTSE 100	7039.81	-1.63	-4.67

Currency	Closing	% Chg	% YTD
USD/INR	80.148	0.34	7.24
EUR/INR	80.0590	0.05	-5.39
EUR/USD	1.0019	0.03	-11.88

Commodity	Closing	% Chg	% YTD
BRENT CRUDE	99.77	0.03	28.32
GOLD/TROY Oz.	1708.75	0.17	-6.93
SILVER/TROY Oz.	18.323	0.54	-21.82

Indian ADRs	Closing	Net Chg	% Chg
Dr. Reddy's Lab	57.32	1.16	2.07
HDFC Bank	57.02	-0.23	-0.40
ICICI Bank	18.89	0.15	0.80
Infosys	17.90	-0.21	-1.16
Tata Motors	26.92	0.30	1.13
Wipro	5.010	-0.100	-1.96

52 Week High		
Script	Closing Price	52 Wk High Price
VBL	838	884
-	-	-
-	-	-

FII & DII Activities (INR Cr)		
Market Segment	Last Trading Session	Year to Date
Index Futures	(602)	(15,436)
Stock Futures	(473)	23,437
Net Future Position	(1,075)	8,001
Index Options	7,037	241,205
Stock Options	(76)	(1,806)
Net Options Position	6,961	239,398
FII In cash Segment	309	(236,092)
DII In cash Segment	(556)	192,928
Net Cash Position	(247)	(43,164)

Stock /Industry Specific News

- ACC reported a 60% on-year decline in consolidated profit at INR 227 crore in quarter ended June 2022 dented by rising global fuel costs and related inflationary impacts. EBITDA fell 51% YoY to INR 426 cr and margin declined by 1,310 bps to 9.7% in Q2CY22. Revenue increased by 15% YoY to INR 4,393 cr with cement sales volumes up 10.5% at 7.56 mn tonnes and ready mix concrete sales volumes up 43.1% at 0.83 mn cubic metres.
- L&T Infotech has reported a net profit of INR 634.40 crore for the first quarter of the current financial year, up 27.7% year-on-year. The company's revenue from operation surged by 30.6% yoy to INR 4,522.8 crore in the quarter. On a quarter-on-quarter basis, the company's revenue rose by 5.1%, while net profit fell 0.5%.
- Life Insurance Corporation The insurance on Thursday said its embedded value stood at INR 5,41,492 crore at the end of March this year compared to INR 95,605 crore in the year-ago period. At the end of September 2021, the value stood at INR 5,39,686 crore.
- Tata Elxsi clocked a robust 63% yoy growth in profit at INR 184.7 cr for Q1FY23 on strong operating profit and topline growth. Revenues from operations at INR 725.9 crore grew by 30% YoY and EBITDA increased 58.8% YoY to 238.2 crore in Q1FY23.
- Cipla announced that its consumer health division, Cipla Health Ltd. (CHL) will acquire Endura Mass from Medinnbelle Herbalcare Private Ltd. Endura Mass is a nutritional supplement brand in the category of weight gain. Post the closure of the proposed acquisition, Cipla Health will distribute and market the product.
- Syngene International has signed 10-year biologics manufacturing agreement with leading animal health company, Zoetis. It will manufacture the drug substance for Librela (bedinvetmab), a monoclonal antibody used for treating osteoarthritis in dogs. Syngene's collaboration with Zoetis has started in 2011.
- The pace of growth in non-food credit grew by 13.8% on year in the fortnight ended July 1, as per data released by the RBI, sustaining double-digit growth for three fortnights in a row. Deposit growth, which had moderated in the previous fortnight ended June 17, also grew 9.77% YoY.
- Bharat Heavy Electricals said it has successfully commissioned 100-MW floating solar photovoltaic plant at NTPC Ramagundam in Telangana. The plant is installed across the natural raw water reservoir, saving valuable land resources, and also conserves water by reducing evaporation.

Key Events Today/ Corporate Actions (Arihant Estimates)

- L&T Technology Q1FY23E: Net Revenue INR 18,078 Mn +19% YoY, EBIT INR 3,265 Mn +24% YoY, PAT INR 2,705 Mn 25% YoY.**

Inside Arihant's Morning Daily

- Cipla Health to acquire Endura Mass; Signs definitive agreements to rope in key products**
- Arihant Model Portfolio**

Cipla Health to acquire Endura Mass; Signs definitive agreements to rope in key products

Cipla Health will immediately initiate the distribution and marketing of the said products pending the closure of the proposed acquisition, the company stated on Thursday.

Cipla Limited on Thursday announced that Cipla Health Limited (CHL) has signed definitive agreements for the acquisition of Endura Mass. According to the company's press statement, Endura and all other associated products would be part of the acquisition.

The company claims that this acquisition is in line with Cipla's strategic imperative to augment the Company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.

"As per the signed definitive agreements, the acquisition is subject to the completion of certain closing conditions. CHL shall immediately initiate the distribution and marketing of the said products pending the closure of the proposed acquisition," the company said in a statement on Thursday.

"With this strategic acquisition, we will be expanding our portfolio into a new category of weight gain, thereby catering to a very specific nutritional need for a set of our consumers. Being underweight is linked to multiple challenges such as poor stamina, poor concentration and low immunity.

The addition of Endura & Endura mass to our portfolio perfectly complements our existing offerings across all key OTC/Wellness categories and would hence help us offer an even more comprehensive solution to all key consumer needs," Shivam Puri, Chief Executive Officer of CHL stated on Thursday.

The company claims that it is well positioned to further build and develop the nutrition supplement category owing to its strong existing offline and online distribution muscle and a deep consumer in sighting engine which has already helped create over 12 strong brands within the portfolio through this acquisition.

Source: Financial Express

Conservative

Symbol	Company	Stock Weightage	Recommendation Date	Recommended Price 03 Jun 19	Last Traded Price 14th July 2022	Absolute Return	Weighted Return
TCS	TCS	5.0%	6/3/2019	2240	2999	33.9%	1.7%
HDFCAMC	HDFC AMC	7.5%	12/4/2019	3329	1898	-43.0%	-3.2%
SBILIFE	SBI Life	12.5%	6/3/2019	693	1139	64.3%	8.0%
PFIZER	Pfizer	7.5%	6/3/2019	3351	4120	23.0%	1.7%
KOTAKBANK	Kotak Bank	12.5%	6/3/2019	1531	1770	15.6%	2.0%
MGL	Mahanagar Gas	7.5%	11/18/2019	1029	795	-22.7%	-1.7%
TATACHEM	Tata Chemicals	7.5%	12/4/2019	304	841	176.7%	13.3%
ICICIBANK	ICICI Bank	5.0%	12/4/2019	529	752	42.1%	2.1%
HDFC	Housing Development	10.0%	12/4/2019	2322	2167	-6.7%	-0.7%
SBICARD	SBI Cards and Payments	12.5%	5/8/2020	553	846	52.9%	6.6%
INFY	Infosys	7.5%	1/10/2020	738	1429	93.6%	7.0%
MGL	Mahanagar Gas	5.0%	5/8/2020	909	795	-12.5%	-0.6%
Portfolio Return						36.2%	
Nifty Return						31.8%	

Arihant Research DeskEmail: instresearch@arihantcapital.com

Tel. : 022-42254800

Head Office	Registered Office
#1011, Solitaire Corporate Park Building No. 10, 1 st Floor Andheri Ghatkopar Link Road Chakala, Andheri (E) Mumbai – 400093 Tel: (91-22) 42254800 Fax: (91-22) 42254880	Arihant House E-5 Ratlam Kothi Indore - 452003, (M.P.) Tel: (91-731) 3016100 Fax: (91-731) 3016199

Stock Rating Scale	Absolute Return
BUY	>20%
ACCUMULATE	12% to 20%
HOLD	5% to 12%
NEUTRAL	-5% to 5%
REDUCE	-5% to -12%
SELL	<-12%

Research Analyst Registration No.	Contact	Website	Email Id
INH000002764	SMS: 'Arihant' to 56677	www.arihantcapital.com	instresearch@arihantcapital.com

Disclaimer: This document has been prepared by Arihant Capital Markets Ltd. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Arihant may trade in investments, which are the subject of this document or in related investments and may have acted upon or used the information contained in this document or the research or the analysis on which it is based, before its publication. This is just a suggestion and Arihant will not be responsible for any profit or loss arising out of the decision taken by the reader of this document. Affiliates of Arihant may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. No matter contained in this document may be reproduced or copied without the consent of the firm.

Arihant Capital Markets Ltd.
1011, Solitaire Corporate park, Building No. 10, 1st Floor,
Andheri Ghatkopar Link Road, Chakala, Andheri (E)
Tel. 022-42254800 Fax. 022-42254880